Filtered By:
Specialty: Health Management
Drug: Diovan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Cost Effectiveness of the First ‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
ConclusionsThis was the first study to evaluate the cost effectiveness of sacubitril/valsartan in the treatment of hypertension. Sacubitril/valsartan compares favorably with allisartan isoproxil and valsartan in the Chinese setting, which is mainly due to its higher efficacy resulting in fewer cardiovascular events and ultimately less related mortality over time. The results could inform deliberations regarding reimbursement and access to this treatment in China and may provide reference for facilitating more reasonable and efficient allocation of limited resources in such low- and middle-income countries.
Source: PharmacoEconomics - September 8, 2022 Category: Health Management Source Type: research
